The 22 references in paper O. Vetchinnikova N., E. Shestero V., E. Еgorova A., О. Ветчинникова Н., Е. Шестеро В., Е. Егорова А. (2017) “МИНЕРАЛЬНО-КОСТНЫЕ НАРУШЕНИЯ У РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТА // MINERAL AND BONE DISORDERS IN RENAL TRANSPLANT RECIPIENTS” / spz:neicon:nefr:y:2016:i:6:p:49-56

1
Kinnaert P, Nagy N, Decoster-Gervy C et al. Persistent Hyperparathyroidism Requiring Surgical Treatment after Kidney Transplantation. World J Surg 2000; 24: 1391–1395
(check this in PDF content)
2
Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281–1287
(check this in PDF content)
3
Kawarazaki H, Shibagaki Y, Fukumoto S et al. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study. TherApher Dial 2011; 15(5): 481–487
(check this in PDF content)
4
Bhan I, Shah A, Holmes J еt al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? Kidney Int 2006; 70: 1486–1494
(check this in PDF content)
5
Evenepoel P, Naesens M, Claes K et al. Tertiary hyperphosphatoninism accentuates hypophosphatemia and suppresses calcitriol level in renal transplant recipients. Am J Transplant 2007; 7: 1193–1200
(check this in PDF content)
6
Evenepoel P, Meijers BK, de Jonge H et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829–1836
(check this in PDF content)
7
Есаян АМ, Каюков ИГ, Нимгирова АН и др. Фактор роста фибробластов 23-го типа у реципиентов почечного аллотрансплантата. Нефрология 2012; 16 (4): 50–54. [Esayan AM, Kayukov IG, Nimgirova AN i dr. Factor rosta fibroblastov 23 tipa u recipientov pochechnogo allotransplantata. Nefrologija 2012; 16 (4): 50–54]
(check this in PDF content)
8
Evenepoel P, Lerut E, Naesens M. Localization, etiology and impact of calcium phosphate deposits in renal allografts. A J Transplant 2009; 9: 2470–2478
(check this in PDF content)
9
Bleskestad IH, Bergrem H, Leivestad T et al. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011; 25: E566–E570
(check this in PDF content)
10
Dumoulin G, Hory B, Nguyen NU et al. No trend towards a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746–753
(check this in PDF content)
11
Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pretransplant PTH concentrations. Nephrol Dial Transplant 1998; 13 [Suppl 3]: 94–97
(check this in PDF content)
12
National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42 (Suppl. 3): S1–S202
(check this in PDF content)
13
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supp 2013; 3(1): 1–150
(check this in PDF content)
14
Нефрология. Клинические рекомендации. Ред.: Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГЭОТАР-Медиа, М., 2016, 816 с. [Nefrologija. Klinicheskie rekomendacii. Red.: Shilov EM, Smirnov AV, Kozlovskaja NL. GEOTAR-Media, M., 2016, 816 s.]
(check this in PDF content)
15
Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011; 15 (4): 11–20 [Dobronravov VA. Sovremenniy vzgliad na patofiziologiyu vtorichnogo giperparatireoza: rol` factora rosta fibroblastov 23 i Klotho. Nefrologija 2011; 15 (4): 11–20]
(check this in PDF content)
16
Гребенникова ТА, Белая ЖЕ, Цориев ТТ и др. Эндокринная функция костной ткани. Остеопороз и остеопатии 2015; 1: 28–37 [Grebennikova TA, Belaya ZhE, Tsoriev TT i dr. Endocrinnaia funkciya kostnoy tkani. Osteoporoz i osteopatii 2015; 1: 28–37]
(check this in PDF content)
17
Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009; 20 (5): 230 – 236. doi: 10.1016/ j.tem.2009.02.001
(check this in PDF content)
18
Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Endocrine Society. Evolution, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930; PMID: 21646368; http:// dx.doi.org/10.1210/ jc.2011-0385
(check this in PDF content)
19
Kim SM, Choi HJ, Lee JP et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Renal Nutr 2014; 24 (1):
(check this in PDF content)
20
25; http:// dx.doi.org/ 10.1053/ j.jrn.2013.07.003 20. Никольская ИГ, Ветчинникова ОН. Влияние беременности и хронической болезни почек на минерально-костный метаболизм. VIII съезд Научного общества нефрологов России. Сборник тезисов. Москва, 11-13 ноября 2015 г. С. 76 [Nikol`skaya IG, Vetchinnikova ON. Vliyanie beremennosti i chronicheskoy bolezni pochek na mineral`niy i kostniy metabolism. VIII s`ezd Nauchnogo obcshestva nefrologov Rossii. Sbornik tezisov. Moskva. S.76]
(check this in PDF content)
21
Wacker M, Holick MF. Vitamin D – effects on skeletal and extraskeletal health and theneed for supplementation. Nutrients 2013; 5: 111–148; PMID: 23306192; http:// dx.doi.org/10.3390/ nu5010111
(check this in PDF content)
22
Schottker B, Haug U, Schomburg L et al. Strong association of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013; 97: 782–793; PMID: 23446902; http:// dx.doi.org/10.3945/ ajcn. 112.047712
(check this in PDF content)